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Abstract: Virus infections elicit an immediate innate response involving antiviral factors. 
The activities of some of these factors are, in turn, blocked by viral countermeasures. The 
ensuing battle between the host and the viruses is crucial for determining whether the virus 
establishes  a  foothold  and/or  induces  adaptive  immune  responses.  A  comprehensive 
systems-level understanding of the repertoire of anti-viral effectors in the context of these 
immediate virus-host responses would provide significant advantages in devising novel 
strategies to interfere with the initial establishment of infections. Recent efforts to identify 
cellular  factors  in  a  comprehensive  and  unbiased  manner,  using  genome-wide  siRNA 
screens and other systems biology ―omics‖ methodologies, have revealed several potential 
anti-viral effectors for viruses like Human immunodeficiency virus type 1 (HIV-1), Hepatitis 
C virus (HCV), West Nile virus (WNV), and influenza virus. This review describes the 
discovery of novel viral restriction factors and discusses how the integration of different 
methods in systems biology can be used to more comprehensively identify the intimate 
interactions of viruses and the cellular innate resistance. 
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1. Introduction 
Humans are constantly threatened by a diversity of viruses, and therefore have developed a variety 
of efficient strategies to fight off infection. Among these strategies, the innate immune system provides 
a  first  line  of  defense  against  pathogens.  Germ-line  encoded  pattern-recognition  receptors  (PRRs) 
recognize  pathogens  and  this  exposure  rapidly  initiates  a  cascade  of  events  that  results  in  the 
expression of a variety of genes involved in inflammatory and immune responses [1]. The Interferon 
(IFN) family of cytokines is recognized as a key innate immune component. Three classes of IFN have 
been  identified  (Type  I,  II  and  III)  that  mediate  through  their  cognate  receptors  the  induction  of  
IFN-stimulated genes (ISGs) with antiviral and antimicrobial activities [2]. As a result, viruses have to 
counter  these  defenses  by  incorporating  tools  that  can  dampen  or  overcome  the  antiviral  host  
defense  [3].  The  presence  of  antiviral  genes  and  ISGs  is  not  limited  to  mammals  and  found,  for 
example, in fish and birds. Examples for genes instigating an antiviral state are PRRs like the toll-like 
receptors and RNA helicases [4]. Prominent examples for the discovery of antiviral effector genes are 
the GTPase Mx1 (myxovirus resistance 1) [5], the protein kinase R (PKR), the 2′,5′-oligoadenylate-
synthetase-directed  ribonuclease  L  pathway  with  the  involved  proteins  OAS  and  RNaseL  and  the  
IFN-stimulated  protein  of  15  kDa  (ISG15)  [2].  This  review  will  concentrate  on  systems-biology 
methods  that  can  be  potentially  applied  to  identify  novel  antiviral  effectors  against  human  viral 
pathogens like HIV-1, HCV and influenza virus. 
2. Employing Systems-Biology Approaches for Unbiased Identification of Anti-Viral Effectors 
The innate immune system is a complex network of interconnected pathways with multifaceted 
feedback  or  feed-forward  loops,  cross-talk  and  diverse  mechanism  of  regulation,  including  
post-transcriptional and post-translational modifications [6]. Another dimension, the interplay of the 
host with various pathogens, adds to this complexity. The host-virus interface is comprised of three 
fundamental  components:  (i)  recognition  and  induction  of  signaling  by  innate  immune  receptors,  
(ii) cellular antiviral responses, and (iii) viral evasion of innate restriction mechanisms. To identify and 
understand  the  effective  response  to  viral  infections,  all  three  components  together  are  important 
players that need to be researched to understand the complex host-pathogen relationship. While a 
candidate gene approach is feasible to begin to dissect the innate immune responses involved in viral 
infections, that methodology also has multiple limitations and disadvantages. Such analyses restrict the 
investigation  to  known  components  and  provide  marginal  systematic  insight  into  the  virus-host 
circuitry  that  mediates  innate  responses  to  viral  infection.  Thus,  it  would  be  unlikely  that  such  a 
reductionist  approach  will  elucidate  combinatorial  effects  and  emergent  properties  of  molecular 
systems  that  ultimately  underlie  the  degree  and  effectiveness  of  cellular  responses  that  lead  to 
restriction of infection. 
By contrast, systems-level analyses theoretically represent comprehensive and unbiased survey of 
the host-pathogen interactions that underlie these innate responses. The integration of high-throughput 
―omics‖  data  such  as  functional  genomics,  transcriptomics,  proteomics,  metabolomics  and  other 
approaches that inform us of networks and dynamic system models can provide global insight towards 
cellular  antiviral  responses  [7,8].  The  assimilation  of  multiple  orthogonal  datasets  can  enable  the Viruses 2011, 3                                       
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discovery  of  a  global  cellular  response  and  regulators  of  the  host-viral  relationship.  Ultimately,  a 
systems-level analysis will shed light on host susceptibility and resistance to infections, and support 
the development of novel classes of immune-mediated antivirals, adjuvants, and vaccines. 
3. Historical Perspective: Discovery of Restriction Factors through Conventional Screening 
Approaches 
Induction of type I interferon regulates the expression of several ISGs that may have direct antiviral 
properties. A group of proteins with potent anti-viral properties known collectively as ―restriction 
factors‖  are  constitutively  expressed  or  induced  by  type-1  interferon  and  are  able  to  limit  viral 
replication by targeting specific steps in the life cycle [9]. In this section, we will summarize the 
discovery of restriction factors for HIV. These factors were identified with the help of classical genetic 
screens or by candidate gene approaches coupled with ―omics‖ technologies. 
It has been well established that HIV-1 variants lacking certain non-structural genes are limited in 
their  ability  to  replicate  in  some  cell  lines,  but  show  productive  infections  in  other  cell  lines.  In 
addition, wild type HIV-1 is unable to perform a complete infection cycle in cells of non-Hominidae 
origin, implicating a species-specific adaptation to viral dependency factors and restriction factors. 
Conventional systems approaches have expressed cellular cDNA libraries to search for dependency 
factors like retroviral receptors or to search for restriction factors like TRIM5α (see below). While 
these methods were quite successful, and identified important proteins they require the knowledge of a 
previously identified phenotype. 
The first restriction factor for HIV-1 was discovered in 2002. It was a well-known phenomenon that 
the  HIV-1  protein  Vif  is  required  to  counteract  a  dominant  inhibitory  factor  [10,11].  Cells  
non-permissive  for  replication  of  Δvif  HIV-1  were  believed  to  express  an  antiviral  protein  that 
inhibited the infectivity of newly produced particles. Sheehy et al. identified this protein, APOBEC3G, 
by a PCR based cDNA subtraction strategy of non-permissive CEM cells and HIV-1 infected CEM-SS 
cells. Candidate cDNAs derived from non-permissive cells were expressed in permissive cells and 
tested for their ability to inhibit viral replication assays [12]. In follow up studies, it was discovered 
that the cytidine deaminase APOBEC3G is encapsidated in Δvif HIV-1 particles, and during the viral 
reverse  transcription,  it  can  deaminate  cytidines  in  the  single  stranded  DNA.  Thus  APOBEC3G 
mutates the viral genomes in target cells and thereby inhibits the replication of HIV [13,14]. The  
HIV-1  Vif  protein  counteracts  APOBEC3G  to  circumvent  this  restriction.  Specifically,  Vif  binds 
APOBEC3G  and  recruits  an  E3  ubiquitin  ligase  complex  that  induces  polyubiquitination  and 
degradation of APOBEC3G in virus-producing cells [15–17]. In addition, the human genome encodes 
six more APOBEC3 proteins (APOBEC3A, -B, -C, -D, -F and -H) that can inhibit various retroviruses, 
endogenous retroelements and DNA viruses [18–22]. 
The resistance of simian cells to HIV-1 was used to identify another restriction protein that blocks 
the  virus  early  post-entry  at  uncoating.  Stremlau  et  al.  used  a  retroviral  cDNA  library  of  rhesus 
macaque cells to transduce permissive human HeLa cells and screened for HIV-1 resistant cells [23]. 
This study revealed that HIV-1 is inhibited by the simian TRIM5α protein, but not by the human 
orthologue.  TRIM5α  is  constitutively  expressed,  but  interferon  treatment  can  further  increase  its  
levels [24]. It is speculated that Rhesus TRIM5α restricts HIV-1 by acceleration of the viral uncoating Viruses 2011, 3                                       
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process that is believed to inhibit the reverse transcription. Inhibition of the proteasome relieves the 
reverse transcription block in cells expressing rhesus TRIM5α, but interestingly, HIV-1 genomes are 
still  blocked  for  integration  [25].  A  very  recent  study  suggests  that  TRIM5α  is  a  multifunctional 
component of the innate immune system, and serves not only as a restriction factor (effector), but can 
also promote innate immune signaling that is triggered by interaction with the retroviral capsid lattice. 
These  data  imply  that  TRIM5α  may  serve  as  a  pattern-recognition  receptor  for  HIV-1  [26]. 
Traditionally, viruses are recognized through innate immune sensors as foreign by their viral nucleic 
acids [27] through cytoplasmic PRRs and viral envelope proteins through TLRs [28]. TRIM5α would 
be the first described innate sensor recognizing HIV-1 capsid. 
Another interferon-induced restriction factor, CD317/BST-2/Tetherin, was independently identified 
by two groups [29,30]. CD317 is neutralized by the HIV-1 protein Vpu. HIV-1 deficient for Vpu is 
unable  to  bud  from  cells  due  to  ‗tethering‘  by  CD317  [29].  Vpu  interferes  with  the  cell  surface 
expression of CD317 partially by inducing its degradation [31,32]. Neil et al. used microarray analysis 
comparing untreated and IFN-a treated cells to identify this HIV-1 restriction factor. Candidate genes 
were  selected  by  filtering  the  results  for  differential  expression  and  localization  of  the  induced  
genes [29]. Targeting of Tetherin/BST-2 by Vpu was also elucidated by Van Damme et al. [30] based 
on a quantitative proteomic approach that identified BST-2 as a target for the gamma-herpesvirus 
immune modulator K5 [33]. 
4. Genomics Technologies Enabled the Discovery of Genome-Wide Host-Pathogen Interactions 
Systems-biology approaches that used genome-wide libraries of siRNAs or shRNAs dramatically 
changed the limitations of the traditionally genetic screens. These experiments were enabled by the 
development and integration of high-throughput technologies. An important challenge using genome 
wide siRNA screens is the implementation of rigid methods to filter the enormous amounts of data and 
identify true hits [34–36]. The detection of potential candidate genes is influenced by many factors like 
timing and filtering thresholds [35]. Meta-analyses, integrating the data with those previously done in 
functional  or  proteomic  studies  will  lead  to  a  list  of  candidate  genes  identified  independently  in 
multiple studies and will increase the chance of calling a true hit [35,37]. 
Most  genome-wide  RNAi  screens  so  far  focused  on  identifying  viral  dependency  factors  that 
facilitate  replication  rather  than  identifying  innate  immune  genes  involved  in  restricting  viral 
replication (Influenza: [38–40]; HIV: [41–43]; Dengue: [44]; HCV: [45]). However, in addition to 
identifying  host  proteins,  some  genome-wide  approaches  captured  possible  innate  effectors  or 
restriction factors. In these screens the inhibition of restrictive proteins resulted in an increase of viral 
replication. For example, the study by Zhou et al. [46], who conducted a genome-scale siRNA screen 
(targeting 19,709 genes) revealed more than 311 host factors important for HIV replication. One gene, 
GM2A (GM2 ganglioside activator) acted as a potential restricting factor for HIV. siRNAs against 
GM2A increased HIV replication 2-fold. 
Restriction factors against human flaviviruses were identified in two siRNAs screens against West 
Nile virus (WNV) and Hepatitis C virus (HCV) [47,48]. Krishnan et al. [47] identified 305 genes 
affecting WNV replication, and of these, 22 genes were found to be potential host resistance factors. 
IRF3, a critical mediator of several known innate response pathways, was amongst those identified. Its Viruses 2011, 3                                       
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identification  suggests  that  genome-wide  genetic  perturbations  screens  and  other  high-throughput 
datasets have the potential to reveal novel factors that not only restrict viruses, but also act as effectors 
of  innate  signaling  cascades.  In  addition,  silencing  of  the  monocarboxylic  acid  transporter  MCT4 
(SLC16A4) delayed the temporal transition into the replication phase of endocytosed WNV particles [47]. 
Interestingly, silencing of all 22 genes enhanced both WNV and Dengue virus 2, speculating that the 
innate pathways and effectors might be a shared host resistance strategy against flaviviruses.  
Li  et  al.  [48]  performed  a  genome-wide  screen  (targeting  19,470  genes)  for  HCV-host  cell 
interactions, and found that 262 genes when silenced decreased viral replication. In addition, this study 
also reported more than 20 factors that may function in anti-viral responses or safeguarding the cells 
against the stress of infection. The anti-viral mechanisms of these potential HCV restriction factors are 
not known.  
Brass et al. [49] discovered 120 dependency factors in their siRNA screen (targeting 17,877 genes) 
for  influenza  A  virus  infection.  This  study  also  identified  a  small  number  of  restricting  proteins: 
PUSL1, TPST1, WDR33, and IFITM1, 2, 3. The interferon-inducible transmembrane proteins (IFITM) 
conferred basal resistance to influenza virus by blocking an early infection step, but are also inducible 
by interferons type I and II. IFITM proteins mediated cellular resistance not only to flu, but also to 
WNV and dengue virus, but not to HCV [49]. Interestingly, Lu et al. [50] could show that IFITM 
proteins are also potent restriction factors of HIV-1 and also inhibit the virus at cell entry. The exact 
mechanism of restriction is currently not known.  
In addition, RNAi studies identified antiviral defense genes in Drosophila, their impact on viruses 
replication in human cells has yet to be elucidated [51]. 
Certain cellular proteins identified as dependency factors might indeed protect the virus against 
unknown  cellular  antiviral  proteins,  a  function  that  is  also  achieved  by  some  viral  non-structural 
proteins like the multifunctional NS1 protein of influenza virus. None of the above mentioned studies 
systematically investigated how non-structural proteins influenced the results of the siRNA screens. In 
addition, none of the above studies conducted their screens in cells induced to be in an antiviral state. 
Also, sentinel cells of the immune system would be more appropriate to screen for antiviral effects. 
Since  these  cells  are  not  easily  transfectible  in  a  high-throughput  fashion,  one  needs  to  think  of 
alternative  cell  models  representing  immune  cells.  A  number  of  screens  mentioned  above  used  
non-replicating  viruses.  Designing  screens  covering  the  whole  life  viral  cycle  will  increase  the 
likelihood of viral PAMPs being recognized and in turn leading to induction of antiviral genes.  
5. Systems-Based Approach to Detect ISGs as Novel Antiviral Effectors  
Numerous gene expression datasets are available to enable a global analysis of the genes involved 
in the IFN response. Those interferon-stimulated genes are the prime candidates for the discovery of 
potential novel antiviral effectors, however innate cellular restriction mechanisms may not be limited 
to the activities of IFNs. Microarray technology (―transcriptomics‖) has enabled us to capture the 
comprehensive picture of changes in the expression profile of cells treated with IFN. The ISG database 
has cataloged hundreds of upregulated genes after stimulation of human HT1080 cells with IFN-α, 
IFN-β  and  IFN-γ  [52]  and  additionally  from  IFN  stimulated  human  dendritic  cells  and  mouse 
embryonic fibroblasts (MEFs) [53]. The dataset contains many previously identified host defense ISGs Viruses 2011, 3                                       
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like PRKR, OAS2 and Mx genes. A second database, the INTERFEROME database, is a collection of 
43 datasets listing ISGs of various sources and can be analyzed using various computational analysis, 
including identification of promoter regulatory elements, tissue expression, protein domains and others 
[54,55] (see list of various databases in Table 1). Another study explored the global transcriptional 
profiles of different immune cell populations in human peripheral blood mononuclear cells (PBMCs) 
upon stimulation with type I and II interferons and factors involved in cell-mediated immunity (IL12 
and TNFα) and allowed the identification of both cytokine-specific and cell-specific transcriptional 
patterns [56]. All three datasets and databases represent powerful resources from which to decipher 
potential anti-viral innate effectors.  
Table 1. Selected bioinformatics resources for innate immune and host-pathogen research. 
Note that some descriptions are quoted directly from the website. 
  Database  Website Link  Details  Reference 
Immune 
Databases 
ISG Database  http://www.lerner.ccf.org/labs/willi
ams/ 
A database for Interferon-stimulated 
genes. Can be queried for functional 
categories 
[52] 
  Interferome 
Database 
http://www.interferome.org/  A database for Interferon-regulated 
genes 
[55] 
  Innate 
Database 
http://www.innatedb.ca/  Innate immunity-relevant 
interactions and pathways 
[64] 
  Reference 
Database of 
immune Cells 
(RefDIC) 
http://refdic.rcai.riken.jp/welcome.c
gi 
Gene expression profiles at the 
mRNA and protein levels for 
Immune cells and tissues 
[85] 
  Innate 
immune 
database 
http://db.systemsbiology.net/cgibin/
GLUE/U54/IIDBHome.cgi 
Information on more than 2000 
mouse genes related to immune 
responses 
[86] 
  PRRDB  http://www.imtech.res.in/raghava/ 
prrdb/ 
Comprehensive database of  
pattern-recognition receptors and 
their ligands 
[87] 
  Immunome  http://bioinf.uta.fi/immunome  Database for genes and proteins of 
the human immune system 
[88] 
  Macrophages
.com 
http://www.macrophages.com/  Broad repository for data and 
information about macrophages 
- 
Host-
Pathogen 
interactions 
Pathogen 
interaction 
gateway 
http://molvis.vbi.vt.edu/pig/ 
 
User interface for searching 
available data and tools to predict 
interactions between host and 
pathogen 
[71] 
  Virusmint  http://mint.bio.uniroma2.it/virusmin
t/Welcome.do 
Collection of interactions between 
human and viral proteins and 
integration into human protein 
interaction network. 
[72,73] 
  HIV-1, 
Human 
Protein 
Interaction 
Database 
http://www.ncbi.nlm.nih.gov/RefSe
q/HIVInteractions/ 
HIV-1, human protein interaction 
data presented here are based on 
literature reports 
[89–91] 
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Table 1. Cont. 
  Database  Website Link  Details  Reference 
Protein-
Protein 
interactions 
HPRD  http://www.hprd.org/  Human proteome-wide database for 
domain architecture, post-
translational modifications, 
interaction networks and disease 
association 
[92] 
  MINT  http://mint.bio.uniroma2.it/mint  Interaction database focused on 
experimentally verified protein-
protein-interactions 
[73] 
  BIND  http://bind.ca  Archive of biomolecular interaction, 
complex and pathway information. 
[93] 
  BIOGRID  http://thebiogrid.org/  Database for genetic and protein 
interaction data from human and 
model organisms 
[94] 
  DIP  http://dip.doe-
mbi.ucla.edu/dip/Main.cgi 
Information on verified protein-
protein interactions complied from 
diverse sources  
[95] 
  STRING  http://string-db.org/  Databank for known and predicted 
direct (physical) and indirect 
(functional) protein associations 
[96] 
Pathways  Reactome  http://www.reactome.org  Literature-curated database of human 
pathways, which contains 
51586 interactions among 1473 
human proteins 
[97,98] 
  KEGG  http://www.genome.jp/kegg  Knowledge base containing genomic, 
chemical and systemic functional 
information 
[99] 
  Pathguide  http://www.pathguide.org/  Collection of biological pathway and 
molecular interaction related 
resources 
[100] 
  PID  http://pid.nci.nih.gov/  Molecular interactions and biological 
processes in biomolecular pathways 
[101] 
Other useful 
sites 
BioGPS  http://biogps.gnf.org  Free customizable gene annotation 
portal 
[102] 
  Symatlas  http://symatlas.gnf.org  Gene expression atlas, integrated into 
BioGPS Portal 
[103] 
  Gene 
Expression 
atlas 
http://www.ebi.ac.uk/gxa/  Curated gene expression archive 
- 
  ArrayExpress 
Archive 
http://www.ebi.ac.uk/arrayexpress/  Database of functional genomics 
experiments 
[104] 
  miRBase  http://www.mirbase.org/  Database of published miRNA 
sequences and annotation 
[105] 
  Cytoscape  http://www.cytoscape.org/  Open source software platform for 
visualizing complex-networks 
[106] Viruses 2011, 3                                       
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In search for anti-HIV ISGs, Barr et al. [57] used transcriptional profiling of interferon treated cells. 
They identified that the TRIM22 protein was able to inhibit HIV-1 particle release, but did not inhibit 
non-related  retroviruses.  TRIM22  was  shown  to  target  the  viral  Gag  protein  by  changing  its 
intracellular Gag trafficking. A focused screen on all members of the TRIpartite interaction Motif 
(TRIM) family of E3 ligases revealed that several family members are restriction factors for HIV and 
act both at early and late stage of the life cycle [58]. 
Global expression profiles can also be used to assess the changes of a host in response to specific 
viral pathogens, ex vivo or in vivo. For instance, comparative studies have led to gene signatures 
associated with pathogenic strains [59–61]. Kobasa et al. [59] investigated the regulation of the host 
response  to  1918  influenza  virus  in  the  bronchi  of  infected  macaques  by  comparison  with  a 
conventional influenza virus and reported a deregulated antiviral response and reduced type-I IFN 
stimulated genes by the pathogenic 1918 strain. A deregulation in 1918 infected macaques was also 
reported by Cilloniz et al. [60], who describe differential changes in inflammatory and cell death 
related genes. The study of Billharz et al. [61] suggests the 1918 NS1 protein as a contributor to such a 
deregulated expression profile. 
Schoggins et al. [62], undertook a global comprehensive approach to screen more than 380 ISGs 
listed in various databases (e.g., the ISG database) on their effect of viral replication of HCV, yellow 
fever virus, WNV, chikungunya virus, Venezuelan equine encephalitis virus, HIV-1 and other viruses. 
They developed a cell-based overexpression assay using a lentiviral cDNA expression system, and 
subsequently challenged these cells with virus to assess the ability of these ISGs to inhibit replication. 
They show that different viruses are targeted by unique sets of ISGs, and that some ISGs have additive 
activity.  Interestingly,  they  reported  that  several  ISGs  including  ADAR,  FAM46C,  LY6E  and 
MCOLN2  enhanced  the  replication  of  certain  viruses,  adding  another  layer  of  complexity  to  the  
system  [62].  This  study  characterized  broad  acting  ISGs  that  inhibited  several  different  viruses, 
including proteins such as IRF1, C6orf150, HPSE, RIG-I, MDA5, NAMPT, IRF7 and IFITM3. Other 
tested ISGs showed only antiviral activity against specific viruses. For instance, genes found to inhibit 
HCV include DDX60, MOV10, MS4A4A, MAP3K14 and SLC1A1. Some of these genes were only 
active in cells that responded to interferon (feedback into IFN signaling pathways), other genes seem 
to act as direct inhibitor of HCV (targeted effector function) as it was shown that a common theme of 
mechanism of antiviral action is translational inhibition. The regulation of the innate antiviral response 
can also be regulated through non-coding microRNAs (miRNAs). The report of Pedersen et al. [63] 
was one of the first studies supporting the idea that cellular miRNAs induced through the IFN system 
can combat viral infection. They showed a differential expression profile of miRNAs upon type I and 
II IFN stimulation and corresponding antiviral effects. Specifically, downregulation of miR-122, that has 
been previously shown to be essential for HCV replication, contributes to the antiviral effect of IFN-β [63]. 
Currently, the innate database (DB) is incorporating information on miRNAs known to regulate an 
innate immunity-relevant gene, thus providing a more comprehensive picture of immunity [6,64]. 
New technologies such as next-generation sequencing are opening up new avenues for scientific 
research by sequencing the total transcriptome including mRNAs, microRNAs and long-coding RNAs. 
Peng et al. [65] performed a comprehensive whole-transcriptome analysis of the host response to 
SARS-CoV infection and observed a differential expression profile of 500 annotated, long ncRNA. Viruses 2011, 3                                       
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Interestingly, 40% of a subset of these ncRNAs was similarly regulated in response to both influenza 
virus and interferon treatments suggesting a host response regulated by innate immunity [65].  
6. Proteomics: The Innate Immune Interactome 
A  comprehensive  identification  and  understanding  of  antiviral  innate  effectors  will  require 
monitoring changes not only in the transcriptome or through genetic perturbations of cells with siRNA 
or cDNA, but also monitoring protein abundance, post-translational modifications and protein-protein 
interaction networks. One of the first compilations of an innate-immune interaction network occurred 
with  the  publication  of  a  manually  constructed  comprehensive  map  of  toll-like  receptor  (TLR) 
signaling  network  [66].  Additionally,  the  InnateDB  project  collates  and  curates  more  than  13,000 
innate-immune-relevant interactions and enhances pathway-specific networks [67]. This database can 
identify network ―hubs‖ (i.e., highly connected nodes) and ―bottlenecks‖ (i.e., key connector proteins 
central to many paths in the network), which are likely to represent key regulatory nodes in the network  
Integrating  the  innate-immune  interactome  with  the  host-viral  protein-protein  interface  would 
provide a clearer picture of the immediate interconnection of viral components with the host cell innate 
pathways. Studying the pair-wise interaction landscape between viral protein and host proteins have 
been undertaken with high-throughput yeast two-hybrid maps. For example, de Chassey et al. provide 
a proteome-wide view of HCV-human protein interactions and discovered that the HCV CORE protein 
was a major perturbator of the insulin, Jak-STAT and TGFb pathways [68]. Jaeger et al. reported a 
method of purification and characterization of HIV-human protein complexes by an AP-MS approach, 
that, in future, will be a powerful tool to identify connections between viral proteins, innate effectors, 
and restriction factors [69].  
Interestingly,  a  recent  study  focused  on  the  collective  global  human-pathogen  protein-protein 
interactions (PPI) network of 190 pathogen strains. The authors found that pathogens, both viral and 
bacterial, tend to interact preferentially with human hub proteins and bottleneck factors in human 
pathways  (proteins  with  many  interacting  partners  or  central to  many  paths in the  network)  [70]. 
Because this meta-analysis used studies applying different methods and goals, some results might 
reflect a selectivity of the initial studies. However, the analyses indicate that pathogens interact with 
these central points since they may control cellular processes that are critical for essential steps in 
pathogen  replication  like  nucleic  acid  metabolism.  Databases  harboring  host-protein  interaction 
include  PIG,  the  pathogen  interaction  gateway,  that  collects  host-pathogen  PPIs  for  206  different 
pathogen strains [71] and, VirusMint [72,73]. 
Complementary to genetic perturbation and gene expression screens, studies on proteome changes 
in  cells  upon  viral  infections  may  provide  additional  critical  understanding  of  the  host-pathogen 
relationship. Added information can include protein degradation or modification through viral proteins 
and changes in subcellular localization. Quantitative mass-spectrometry can be used to measure protein 
abundance, post-translational protein modifications and macromolecular complexes. Several proteomic 
analyses on the global changes in the proteome after HIV-1 infection have recently been published. 
Chan et al. used liquid chromatography-mass spectrometry coupled with stable isotope labeling and 
the  accurate  mass  and  time  tag  approach  for  a  quantitative  analysis  that  revealed  changes  in 
ubiquitination [74]. Two years later, the same group published a shotgun liquid chromatography-tandem Viruses 2011, 3                                       
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mass spectrometry analysis uncovering two distinct proteomic abundance profiles at two phases in 
replication  [75].  A  third  group  revealed  a  metabolic  rerouting  of  HIV  infected  T  cells  by  using  
two-dimensional differential in-gel electrophoresis proteomic analysis [76]. 
Global proteomic and metabolomics profiling study has also been used to identify the metabolic 
interplay occurring during infection with HCV [77]. Integrating computational modeling approaches 
revealed that mitochondrial fatty acid oxidation enzymes are differentially regulated both in culture 
and in HCV-infected patients. This study highlights the potential of complementary approaches to 
elucidate mechanisms by which viruses take over cellular resources for their own replicative advantage.  
Proteome-wide analyses, like transcriptomics, do not automatically reveal the factors that act as 
antiviral effectors. Use of virus mutants, or cells that have defined defects in the innate pathways, can 
help to identify candidate genes or the direct action of viral proteins on cellular proteins. 
7. The Advantage of Integrating Systems Approaches 
A biological system, like a host-viral relationship, operates through the concerted action of different 
classes of molecules (DNA, RNA, proteins, metabolites). For each class, ―omics‖ technologies reveal a 
global view and can be integrated using computational techniques to create underlying networks and 
reveal  over-represented  functional  classes.  Each  network  represents  a  specific  type  of  interaction 
involving  different  components,  such  as  genes,  transcripts,  regulatory  RNAs,  proteins,  modified 
proteins  and  metabolites.  Those  networks  are  highly  interconnected  and  dynamic.  For  instance,  a 
miRNA can regulate pairs of interacting proteins and in turn, a protein complex might regulate the 
activity of regulatory RNA. Only the integration of ―omics‖ datasets will lead to a comprehensive view 
of all processes [78]. For example, a recent study on the reconstruction of a transcriptional network 
mediating pathogen responses exemplifies the advantages of dynamic integration of datasets. Genome-
wide mRNA expression profiling upon pathogen stimuli revealed 125 candidate transcription factors, 
chromatin modifiers and RNA binding proteins. Silencing of the candidates in presence of the stimulus 
resulted in a gene signature that enabled the construction of a regulatory network model of 24 core 
regulators and 76 fine-tuners. This model helped to explain how pathogen-sensing pathways achieve 
specificity  [79].  In  addition,  the  importance  of  understanding  the  temporal  codes  of  intra-cellular 
signaling is becoming increasingly recognized [80].  
Similarly,  Shapira  et  al.  integrated  a  multi-layered  approach  to  uncover  dynamic  interactions 
between H1N1 influenza virus and its human host [81]. They integrated protein-protein interaction 
data  (yeast  two-hybrid  approach  to  generate  a  human  protein  network  interacting  with  influenza 
proteins),  genome-wide  expression  profiling,  functional  genomics  and  network  modeling.  Four 
different  strategies  were  used  to  delineate  the  transcriptional  response  to  infection:  Infection  with  
wild-type influenza virus; infection with a virus lacking NS1, which is impaired in counteracting the 
antiviral  host  response;  stimulation  with  IFNβ  and  transfecting  viral  RNA  that  triggers  the  
RNA-sensing  pathway.  A  comprehensive  map  of  physical  and  regulatory  interactions  between 
influenza and its host was constructed. This led to 1745 selected candidate genes that may play a role 
in host responses. The functional contribution of these genes to viral replication and IFN production 
was  then  tested  by  siRNA  knockdown.  This  allowed  the  assignment  of  specialized  roles  in  the  
host-pathogen  network  to  each  candidate  gene  product.  Many  known  host  responses,  (e.g.,  RIG-I Viruses 2011, 3                                       
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mediated sensing), but also several novel pathways were identified, (e.g., a group of inflammasome-
related  sensors  and  a  group  of  proteins  that  is  essential  for  the  control  of  virus  replication  
(e.g., USHBP1, ZMAT4 and MAGEA11)). This broad and unbiased integration of various datasets in 
a  model  of  viral-host  interactions  provides  a promising  direction  for  future  studies.  Although  not 
focused on innate effectors and signaling components, but on host dependency factors, several studies 
exemplify the integration of multiple datasets to derive sub-networks with over-represented functions 
that are important for (i) the influenza-host relationship [37,40], or (ii) affecting distinct steps in the 
life cycle of HIV-1 [42]. In addition, a meta-analysis surveyed several genome-wide datasets to yield a 
more corroborated set of host cell factors assisting HIV replication. These genes then were used to 
calculate refined protein clusters specifying cellular subsystems recruited by HIV [35]. Therefore, 
integration  of  multiple  datasets  is  effective  in  discerning  cellular  networks  important  for  the  
host-viral interface, and can help define the most attractive targets for the development of novel HIV 
therapeutics [35]. 
8. Major Challenges in Systems-Biology Research on Host-Viral Interactions 
Systems-biology  datasets  are  inherent  to  (prone  to)  approach-specific  limitations.  Factors  like 
experimental assay design, choice of reagents, the existence of false positive and negative activities 
and furthermore bioinformatics analyses and hit selection contribute to the variance between datasets 
and the complexity of the final results [82]. Lessons learned from siRNA screening for HIV-1 or 
Influenza host factors: overlaps between datasets are limited when analyzed at the gene level [82,83], 
however  the  concordance  is  greater  at  the  level  of  gene  function  or  protein  complexes  [35,37].  
Off-target activities are an inherent problem of large-scale siRNA screening and can be reduced by 
increasing  the  confidence  in  potential  hits  through  secondary  validation  assays  (cDNA  rescue 
experiments), bioinformatic approaches (to identify at least two hit siRNAs targeting the same gene) 
and integrating several datasets [34,84]. A major factor to consider is the ―bias‖ that is introduced 
through  the  necessity  of  hit  selection.  While  all  ―omics‖  approaches  start  out  with  an  unbiased 
approach, the choice of criteria used to rank the hits will automatically introduce a bias. The future 
challenge will be to reduce this bias by integrating several systems-level datasets (as discussed in 
Section 6), to organize and interpret the generated information and build models that then in turn can 
be tested experimentally and iteratively refined.  
Systems-biology approaches are being employed to complete the picture of the innate pathways 
sensing viral pathogens and of viral-specific ISGs, however, important questions and answers are still 
outstanding.  (i)  A  systematic  survey  of  viral  proteins  or  protein-domains  counteracting  the  innate 
responses. (ii) The impact of variability of different virus strains on the innate immune recognition and 
antagonizing the cellular effectors (e.g., pathogenic versus non-pathogenic strains; pandemic versus 
non-pandemic  strains).  (iii)  The  impact  of  natural  variation  in  the  human  population.  (iv)  The 
discrimination  of  the  innate  system  between  different  pathogens  and  danger  signals  to  mount  an 
appropriate  response.  The  ultimate  goal  of  the  systems-based  approaches  will  be  to  enable  the 
development of therapeutic strategies for antivirals that interfere with viral evasion of host immune 
defenses. Also, a more global understanding of the innate immune response may lay the groundwork 
for  improving  vaccination  strategies.  Realizing  this  vision  will  depend  on  the  formation  of  broad Viruses 2011, 3                                       
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research  consortia  sharing  their  knowledge  and  resources  with  the  community  and  combining  the 
wealth of information in intelligent and user-friendly public databases.  
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